Metabolic measurement | Incidence of potentially clinically relevant fasting metabolic abnormalities, n (%) | Mean (SE) fasting metabolic parameters, mg/dL | ||||
---|---|---|---|---|---|---|
Bupropion plus aripiprazole | SSRI/SNRI plus aripiprazole | Bupropion plus aripiprazole1 | SSRI/SNRI plus aripiprazole2 | |||
Baseline | Change from baseline at Week 52 | Baseline | Change from baseline at Week 52 | |||
Glucose | 3/36 (8.3) | 35/201 (17.4) | 95.0 (2.4) | 1.4 (1.9) | 94.4 (1.3) | 2.7 (1.5) |
Total cholesterol | 9/36 (25.0) | 70/202 (34.7) | 209.6 (6.3) | -0.9 (6.6) | 214.2 (3.2) | -0.9 (2.6) |
LDL cholesterol | 3/35 (8.6) | 48/202 (23.8) | 121.6 (5.3) | 0.5 (5.7) | 125.1 (2.9) | -3.1 (2.5) |
HDL cholesterol | 1/36 (2.8) | 6/202 (3.0) | 55.0 (3.0) | 0.3 (1.4) | 56.4 (1.2) | -0.5 (0.7) |
Triglycerides | ||||||
Male | 9/13 (69.2) | 34/65 (52.3) | 183.0 (36.6) | 7.5 (13.7) | 180.0 (13.9) | 28.2 (19.9) |
Female | 15/23 (65.2) | 100/137 (73.0) | 157.5 (16.0) | -25.3 (8.9) | 156.9 (9.7) | 8.5 (7.1) |